Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00073736 · ClinicalTrials.gov registry record · Phase 1
Safety and Tolerability of I.V. Infusion of MB07133 in Patients With Unresectable Hepatocellular Carcinoma
A Phase 1 study, sponsored by Ligand Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT00073736 is a Phase 1 study that has completed, run by Ligand Pharmaceuticals. The registered enrollment target is 28 participants.
The verdict
NCT00073736, a Phase 1 study, has completed, sponsored by Ligand Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
Hepatocellular carcinoma (HCC) is the most common primary cancer of the liver. MB07133 is being developed for the treatment of inoperable HCC, using a platform technology known as HepDirectTM, which enables drugs to be targeted specifically to the liver. The objective for this study is to determine the safety and tolerability of MB07133.
Interventions
- DRUG MB07133 300mg/m2/day
- DRUG MB07133 600 mg/m2/day
- DRUG MB07133 1200 mg/m2/day
- DRUG MB07133 1800 mg/m2/day
- DRUG MB07133 2400 mg/m2/day
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2003-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00073736
The ClinicalTrials.gov registry entry for NCT00073736 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ligand Pharmaceuticals, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which MB07133 300mg/m2/day is the first listed.
NCT00073736 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00073736 about?
NCT00073736 is a clinical study titled "Safety and Tolerability of I.V. Infusion of MB07133 in Patients With Unresectable Hepatocellular Carcinoma". Hepatocellular carcinoma (HCC) is the most common primary cancer of the liver. MB07133 is being developed for the treatment of inoperable HCC, using a platform technology known as HepDirectTM, which enables drugs to be targeted specifically to the liver. The objective for this study is to determine ...
What is the current status of trial NCT00073736?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2003-09.
What interventions are being tested in trial NCT00073736?
The interventions under investigation include: MB07133 300mg/m2/day (DRUG), MB07133 600 mg/m2/day (DRUG), MB07133 1200 mg/m2/day (DRUG), MB07133 1800 mg/m2/day (DRUG), MB07133 2400 mg/m2/day (DRUG).
Who is sponsoring clinical trial NCT00073736?
This trial is sponsored by Ligand Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.